RHHBY - Roche Holding AG
| Previous Close | 34.47 |
| Open | 33.57 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 33.49 - 33.83 |
| 52 Week Range | 28.74 - 35.90 |
| Volume | 1,220,171 |
| Avg. Volume | 1,181,074 |
| Market Cap | 229.321B |
| Beta (3Y Monthly) | 0.46 |
| PE Ratio (TTM) | 21.94 |
| EPS (TTM) | 1.54 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.07 (3.12%) |
| Ex-Dividend Date | 2019-03-07 |
| 1y Target Est | 37.90 |
- Zacks•4 hours ago
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.
- Zacks•5 hours ago
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
- Zacks•yesterday
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
- Zacks•yesterday
IVD Market Sustains Momentum: 3 Stocks in Focus
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
- Benzinga•yesterday
The Most Actively Traded Securities On OTC Markets In June
There are over 10,000 securities traded on the OTC Markets, 1,430 of which trade on the market’s top two tiers, OTCQX and OTCQB. But when it comes to the most actively traded of those securities, there ...
- Motley Fool•2 days ago
The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.
- Zacks•2 days ago
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
- Zacks•2 days ago
Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.
- Zacks•2 days ago
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
- Zacks•3 days ago
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
- Zacks•3 days ago
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
- Zacks•3 days ago
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
- Zacks•4 days ago
J&J Submits BLA for Subcutaneous Formulation of Darzalex
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
- Zacks•4 days ago
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
- Zacks•7 days ago
Amgen & Novartis' Alzheimer Studies End in Another Failure
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
- Zacks•7 days ago
Aimmune Down on Negative ICER Review on Allergy Candidate
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
- Zacks•7 days ago
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
- Zacks•8 days ago
Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?
Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.
- Investor's Business Daily•8 days ago
Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
- Zacks•10 days ago
Novo Nordisk Reports Encouraging Data From Hemophilia Studies
Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.
- Zacks•10 days ago
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
- Benzinga•10 days ago
The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 8) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Inspire ...
- Business Wire•10 days ago
Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress
OTCQX: RHHBY), announced today new data for Hemlibra® (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on July 6-10 in Melbourne, Australia. In total, Genentech presented 21 abstracts from its hemophilia program, including five oral presentations.
- GlobeNewswire•10 days ago
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
OTCQX: RHHBY) today announced new data for Hemlibra® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia. In total, Roche presented 21 abstracts from its haemophilia programme, including five oral presentations.
- Reuters•11 days ago
Roche, Spark push back takeover deadline in $4.3 billion deal
Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.
